Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic

V. Mravčík, B. Janíková, B. Drbohlavová, P. Popov, A. Pirona,

. 2018 ; 15 (1) : 60. [pub] 20181204

Language English Country England, Great Britain

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19028024

Grant support
NV16-28157A MZ0 CEP Register

Opioid agonist therapy (OAT) has been available in a standard regime in the Czech Republic since 2000. Buprenorphine is the leading medication, while methadone is available only in a few specialised centres. There is an important leakage of buprenorphine onto the illicit market, and the majority of Czech opioid users are characterised by the misuse (and injecting) of diverted buprenorphine medications. Most prescribed buprenorphine for OAT is not covered by current national health insurance schemes, and patients have to pay considerable prices to afford their treatment. This affordability barrier together with limited accessibility is likely the leading factor of limited coverage of OAT and of recent stagnation in the number of patients in the official treatment programmes in the Czech Republic. It also encourages doctor shopping and the re-selling of parts of their medication at a higher price, which represents the main factor that drives the Czech illicit market for buprenorphine, but at the same time co-finances the medication of clients in official OAT programmes. Improving access to OAT by making it financially affordable is essential to further increase OAT coverage and is one of the factors that can reduce the illicit market with OAT medications.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028024
003      
CZ-PrNML
005      
20190822125138.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12954-018-0268-0 $2 doi
035    __
$a (PubMed)30514306
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mravčík, Viktor $u Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. mravcik.viktor@vlada.cz. National Institute of Mental Health, Klecany, Czech Republic. mravcik.viktor@vlada.cz. National Monitoring Centre for Drugs and Addiction, Office of the Government of the Czech Republic, Prague, Czech Republic. mravcik.viktor@vlada.cz.
245    14
$a The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic / $c V. Mravčík, B. Janíková, B. Drbohlavová, P. Popov, A. Pirona,
520    9_
$a Opioid agonist therapy (OAT) has been available in a standard regime in the Czech Republic since 2000. Buprenorphine is the leading medication, while methadone is available only in a few specialised centres. There is an important leakage of buprenorphine onto the illicit market, and the majority of Czech opioid users are characterised by the misuse (and injecting) of diverted buprenorphine medications. Most prescribed buprenorphine for OAT is not covered by current national health insurance schemes, and patients have to pay considerable prices to afford their treatment. This affordability barrier together with limited accessibility is likely the leading factor of limited coverage of OAT and of recent stagnation in the number of patients in the official treatment programmes in the Czech Republic. It also encourages doctor shopping and the re-selling of parts of their medication at a higher price, which represents the main factor that drives the Czech illicit market for buprenorphine, but at the same time co-finances the medication of clients in official OAT programmes. Improving access to OAT by making it financially affordable is essential to further increase OAT coverage and is one of the factors that can reduce the illicit market with OAT medications.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    12
$a opioidní analgetika $7 D000701
650    12
$a buprenorfin $7 D002047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dostupnost zdravotnických služeb $x statistika a číselné údaje $7 D006297
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a methadon $x terapeutické užití $7 D008691
650    _2
$a lidé středního věku $7 D008875
650    _2
$a narkotika $x terapeutické užití $7 D009294
650    _2
$a opiátová substituční terapie $x statistika a číselné údaje $7 D058850
650    _2
$a poruchy spojené s užíváním opiátů $x epidemiologie $x rehabilitace $7 D009293
650    _2
$a zakázané drogy $7 D013287
650    _2
$a poruchy spojené s užíváním psychoaktivních látek $x epidemiologie $7 D019966
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Janíková, Barbara $u Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. National Monitoring Centre for Drugs and Addiction, Office of the Government of the Czech Republic, Prague, Czech Republic.
700    1_
$a Drbohlavová, Barbora $u Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. National Institute of Mental Health, Klecany, Czech Republic. National Monitoring Centre for Drugs and Addiction, Office of the Government of the Czech Republic, Prague, Czech Republic.
700    1_
$a Popov, Petr $u Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
700    1_
$a Pirona, Alessandro $u European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal.
773    0_
$w MED00175640 $t Harm reduction journal $x 1477-7517 $g Roč. 15, č. 1 (2018), s. 60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30514306 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822125417 $b ABA008
999    __
$a ok $b bmc $g 1433173 $s 1066484
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 15 $c 1 $d 60 $e 20181204 $i 1477-7517 $m Harm reduction journal $n Harm Reduct J $x MED00175640
GRA    __
$a NV16-28157A $p MZ0
LZP    __
$a Pubmed-20190813
Back

Find record

Citation metrics

Archiving options